There were 843 press releases posted in the last 24 hours and 168,868 in the last 365 days.

CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

/EIN News/ -- NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

DBV Technologies S.A. (NASDAQ: DBVT)
Class Period:
February 14, 2018 - December 19, 2018
Lead Plaintiff Deadline: March 18, 2019
Join the action: https://www.zlk.com/pslra-1/dbv-technologies-s-a-loss-form?wire=3

The lawsuit alleges: DBV Technologies S.A. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) DBV Technologies' Biologics License Application ("BLA") for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls; (2) consequently, DBV Technologies voluntarily withdrew the BLA for Viaskin Peanut; and (3) as a result, defendants' statements about DBV Technologies' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the DBV Technologies S.A. class action contact jlevi@levikorsinsky.com.

AxoGen, Inc. (NASDAQ: AXGN)
Class Period:
August 7, 2017 - December 18, 2018
Lead Plaintiff Deadline: March 11, 2019
Join the action: https://www.zlk.com/pslra-1/axogen-inc-loss-form?wire=3

The lawsuit alleges that, during the class period, AxoGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company aggressively increased prices to mask lower sales; (2) the Company’s pricing alienated customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) the Company’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics, such as number of active accounts, were overstated; and (11) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the AxoGen, Inc. class action contact jlevi@levikorsinsky.com.

Alkermes plc (NASDAQGS: ALKS)
Class Period:
February 17, 2017 - November 1, 2018
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/alkermes-plc-loss-form?wire=3

The lawsuit alleges: Alkermes plc made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Alkermes plc class action contact jlevi@levikorsinsky.com.

ProShares Short VIX Short-Term Futures (NYSEArca: SVXY)
Class Period:
Investors in ProShares Short VIX Short-Term Futures ETF pursuant to the May 15, 2017 Registration Statement and/or between May 15, 2017 and February 5, 2018
Lead Plaintiff Deadline: April 1, 2019
Join the action: https://www.zlk.com/pslra-1/proshares-short-vix-short-term-futures-loss-form?wire=3

The lawsuit alleges that, during the class period, ProShares Short VIX Short-Term Futures made materially false and/or misleading statements and/or failed to disclose that: According to the complaint in the Registration Statement and during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding the risks of investing in the Fund. Specifically, the Registration Statement failed to disclose that the Fund was threatened with catastrophic losses as a result of the Fund’s flawed design and the low-volatility environment and acute liquidity risks that existed during the Class Period. In addition, during the Class Period defendants made similar false and misleading statements in numerous financial reports and draft prospectuses and registration statements filed with the SEC.

To learn more about the ProShares Short VIX Short-Term Futures class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

250x148_zlk.jpg